Scholarlink

<p>Antimicrobial peptides (AMPs) are considered one of the most promising new antimicrobial agents to combat antibiotic resistance and have garnered significant attention over the past few decades. However, their development has been hindered by high manufacturing costs, toxicity, and poor enzyme tolerance. In this study, we employed bioinformatics tools to simulate the trypsin cleavage of Esculentin-2P (E2P), a frog-derived AMP with 37 amino acids and performed functional screening to identify its effective active fragments. Building on the best derivative, des-(Asp20-Cys37)-E2P, which demonstrated considerable antimicrobial activity, minimal haemolysis, and low cytotoxicity, we introduced the naturally occurring antimicrobial amino acid homo-arginine for further modification. The results showed that the derivate, [hArg<sup>7,11,15,19</sup>]-des-(Asp20-Cys37)-E2P, not only optimised the antimicrobial activity of des-(Asp<sup>20</sup>-Cys<sup>37</sup>)-E2P but also exhibited lower toxicity with a selectivity index of 40.6, improved tolerance to variable environments such as salts, heat, and trypsin, and a reduced likelihood of resistance development. Mechanism studies revealed that the peptide exerts its bactericidal effects by disrupting the bacterial membrane. Additionally, it demonstrated strong therapeutic efficacy in treating <i>Galleria mellonella</i> models infected with drug-resistant <i>Escherichia coli</i>. These results suggest that [hArg<sup>7,11,15,19</sup>]-des-(Asp20-Cys37)-E2P held great promise as a novel antimicrobial candidate against resistant pathogens. The cleavage-mimic truncation strategy, combined with the incorporation of homo-arginine, offers valuable insights for developing potent, shorter AMPs with enhanced therapeutic potential. This approach may help address some key challenges in peptide-drug development, paving the way for more effective antimicrobial therapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Enhancing the selectivity and conditional sensitivity of an antimicrobial peptide through cleavage simulations and homoarginine incorporation to combat drug-resistant bacteria

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Keyi Yao,
  • Jiachen Liu,
  • Ruize Sun,
  • Yun Wang,
  • Yangyang Jiang,
  • Tao Wang,
  • Xiaoling Chen,
  • Chengbang Ma,
  • Tianbao Chen,
  • Chris Shaw,
  • Mei Zhou,
  • Lei Wang

摘要

Antimicrobial peptides (AMPs) are considered one of the most promising new antimicrobial agents to combat antibiotic resistance and have garnered significant attention over the past few decades. However, their development has been hindered by high manufacturing costs, toxicity, and poor enzyme tolerance. In this study, we employed bioinformatics tools to simulate the trypsin cleavage of Esculentin-2P (E2P), a frog-derived AMP with 37 amino acids and performed functional screening to identify its effective active fragments. Building on the best derivative, des-(Asp20-Cys37)-E2P, which demonstrated considerable antimicrobial activity, minimal haemolysis, and low cytotoxicity, we introduced the naturally occurring antimicrobial amino acid homo-arginine for further modification. The results showed that the derivate, [hArg7,11,15,19]-des-(Asp20-Cys37)-E2P, not only optimised the antimicrobial activity of des-(Asp20-Cys37)-E2P but also exhibited lower toxicity with a selectivity index of 40.6, improved tolerance to variable environments such as salts, heat, and trypsin, and a reduced likelihood of resistance development. Mechanism studies revealed that the peptide exerts its bactericidal effects by disrupting the bacterial membrane. Additionally, it demonstrated strong therapeutic efficacy in treating Galleria mellonella models infected with drug-resistant Escherichia coli. These results suggest that [hArg7,11,15,19]-des-(Asp20-Cys37)-E2P held great promise as a novel antimicrobial candidate against resistant pathogens. The cleavage-mimic truncation strategy, combined with the incorporation of homo-arginine, offers valuable insights for developing potent, shorter AMPs with enhanced therapeutic potential. This approach may help address some key challenges in peptide-drug development, paving the way for more effective antimicrobial therapies.